Detalles de la búsqueda
1.
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Cost Eff Resour Alloc
; 22(1): 21, 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459569
2.
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.
Mycoses
; 66(5): 405-411, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36670539
3.
Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city.
J Antimicrob Chemother
; 77(3): 753-757, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849943
4.
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital.
Infection
; 50(1): 191-201, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34406606
5.
Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier.
Cost Eff Resour Alloc
; 20(1): 67, 2022 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36503527
6.
Facilitators and barriers for the implementation of resuscitation training programmes for schoolchildren: A systematic review.
Eur J Anaesthesiol
; 39(8): 711-719, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34860715
7.
Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals.
Mycoses
; 64(1): 86-94, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33034927
8.
Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-The example of isavuconazole.
Mycoses
; 64(10): 1213-1222, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34134179
9.
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
BMC Health Serv Res
; 21(1): 939, 2021 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496836
10.
Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis.
JAC Antimicrob Resist
; 5(3): dlad079, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37342199
11.
Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany.
Healthcare (Basel)
; 10(12)2022 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36554068
Resultados
1 -
11
de 11
1
Próxima >
>>